BIOXCEL THERAPEUTICS INC

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 09075P204 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Armistice Capital, LLC 13G/A Amendment 1	4.99%	1,621,716	13G/A Amendment 1	8/14/2026 Event 6/30/2026
Armistice Capital, LLC	4.99%	1,621,716
Steven Boyd	4.99%	1,621,716
Armistice Capital, LLC 13G	7.1%	1,910,076	13G	5/15/2026 Event 3/31/2026
Armistice Capital, LLC	7.1%	1,910,076
Steven Boyd	7.1%	1,910,076
Integrated Core Strategies (US) LLC 13G/A Amendment 1	8.4%	1,835,192	13G/A Amendment 1	2/9/2026 Event 12/31/2025
Integrated Core Strategies (US) LLC	8.4%	1,833,717
Millennium Management LLC	8.4%	1,835,192
Millennium Group Management LLC	8.4%	1,835,192
Israel A. Englander	8.4%	1,835,192
Integrated Core Strategies (US) LLC 13G	5.2%	1,028,053	13G	10/1/2025 Event 9/29/2025
Integrated Core Strategies (US) LLC	5.2%	1,026,054
Millennium Management LLC	5.2%	1,028,053
Millennium Group Management LLC	5.2%	1,028,053
Israel A. Englander	5.2%	1,028,053
Armistice Capital, LLC 13G/A Amendment 1	4.99%	288,131	13G/A Amendment 1	5/15/2025 Event 3/31/2025
Armistice Capital, LLC	4.99%	288,131
Steven Boyd	4.99%	288,131
Armistice Capital, LLC 13G	10.0%	4,997,275	13G	2/14/2025 Event 12/31/2024
Armistice Capital, LLC	10.0%	4,997,275
Steven Boyd	10.0%	4,997,275

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q3	1	25.0	$1.00	$0
2026 Q2	47	6.18 M	$8.69 M	$0
2026 Q1	40	5.44 M	$7.28 M	$0
2025 Q4	42	3.54 M	$5.67 M	$0
2025 Q3	36	2.36 M	$6.05 M	$0
2025 Q2	36	618 k	$1.19 M	$0
2025 Q1	32	379 k	$770 k	$0